Results 111 to 120 of about 13,126 (223)

Postmarketing Commitment [PDF]

, 2020
openaire   +1 more source

Postmarketing Surveillance [PDF]

, 2020
openaire   +1 more source

Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products. [PDF]

Oncologist
Xiong Y, Konicki R, Zirkelbach JF, Bi Y, Okusanya O, Shord S, Rahman NA, Booth B, Li Y, Liu J, Zhu H.   +10 more
europepmc   +1 more source

Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review. [PDF]

Front Immunol
Zhou J, Wang H, Xie H, Xu X, Xiao H.
europepmc   +1 more source

Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment: Postmarketing Surveillance Study in Japan. [PDF]

JACC Asia
Sakamoto K, Ishihara M, Kato H, Kim H, Okuda M, Hiroki S, Koga M, Toyoda K.   +7 more
europepmc   +1 more source

Postmarketing safety of bimekizumab for hidradenitis suppurativa: An early pharmacovigilance analysis using the United States Food and Drug Administration Adverse Event Reporting System. [PDF]

JAAD Int
Alomary SA, Baker NJ, Ogunleye T, Taylor SC.   +3 more
europepmc   +1 more source

Premarket and postmarket real-world evidence studies supporting U.S. Food and Drug Administration regulatory decision-making, 2016-2024. [PDF]

Clin Trials
Li LY, Ramachandran R, Ross JS, Wallach JD.   +3 more
europepmc   +1 more source

Current and Ongoing Clinical Studies. [PDF]

Muscle Nerve
Abrahao A, Zinman L, Apple S.
europepmc   +1 more source

Postmarketing surveillance of elobixibat for patients with chronic constipation and concomitant schizophrenia or depression in Japan. [PDF]

Front Psychiatry
Takekita Y, Umeyama M, Iwaida M, Higashikawa M, Shimada Y, Nakajima A.   +5 more
europepmc   +1 more source

Postmarketing Cases of Erdafitinib-Associated Skeletal Growth Toxicity Events in Pediatric Patients. [PDF]

Pediatr Blood Cancer
Nadeau Nguyen M, Dores GM, Nayernama A, Jones SC.   +3 more
europepmc   +1 more source